GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Alkem Laboratories Ltd

Alkem Laboratories Reports Record FY26 EBITDA & Strong Q4 Revenue Growth

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 28 May 2026, 01:39 PM IST  ·  BSE ID: 8ebd43ce-de1a-49c8-846c-54a8c4170a79
View Original BSE Filing (PDF)
💡
In Simple Terms
Alkem Laboratories announced strong annual earnings with record profits, driven by higher sales both in India and internationally.
🤖 AI Summary
  • Alkem Laboratories reported a record high EBITDA of ₹30,052 million for FY26, representing 19.6% YoY growth.
  • Total revenue from operations in Q4 FY26 was ₹36,033 million, showing a 14.6% YoY increase.
  • International sales for Q4 FY26 increased by 25.4% YoY to ₹12,223 million, contributing 34.0% to total revenue.
  • Q4 FY26 Net Profit (after Non-Controlling interest) declined by 22.7% YoY to ₹2,365 million.
  • The company filed 5 ANDAs and received 4 ANDA approvals in Q4 FY26 for the US market.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Revenue from Operations Q4 FY26
₹36,033 million
14.6%
India Sales Q4 FY26
₹23,245 million
8.8%
International Sales Q4 FY26
₹12,223 million
25.4%
EBITDA Q4 FY26
₹5,174 million
32.2%
EBITDA Margin Q4 FY26
14.4%
Profit before tax (before exceptional item) Q4 FY26
₹5,578 million
40.7%
Net Profit (after Non-Controlling interest) Q4 FY26
₹2,365 million
-22.7%
Total Revenue from Operations FY26
₹147,123 million
13.5%
India Sales FY26
₹98,514 million
9.7%
International Sales FY26
₹46,810 million
22.5%
EBITDA FY26
₹30,052 million
19.6%
EBITDA Margin FY26
20.4%
Net Profit (after Non-Controlling interest) FY26
₹23,018 million
6.3%
US Sales Q4 FY26
₹7,681 million
26.2%
Non-US Sales Q4 FY26
₹4,543 million
24.1%
🏢 How This Affects the Company
📈
Business Impact
The company's top-line growth was broad-based, with both domestic branded generics and international business segments delivering strong growth, outperforming the Indian Pharmaceutical Market (IPM) in key therapies.
💰
Financial Impact
Alkem achieved a record high EBITDA of ₹30,052 million in FY26, with an EBITDA margin expansion to 20.4% from 19.4% in FY25, indicating improved operational profitability despite a Q4 net profit decline due to exceptional items.
⚙️
Operational Impact
R&D expenses increased to ₹6,173 million for FY26, accounting for 4.2% of total revenue, supporting a differentiated launch pipeline for international markets and an increasing contribution from chronic therapies.
⚠️
Risk Impact
The Daman (India) Formulations facility received a Form 483 with 7 observations in April 2026, with the audit response currently under submission, which presents a regulatory compliance monitoring point.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this filing, as it primarily provides financial performance updates.
👤
Who Is Affected
All shareholders are affected as the company's financial results determine its overall health and potential for future value creation. The Q4 net profit decline impacts current earnings per share.
🔍
Management Signal
Management indicates a focus on broad-based top-line growth, operational rigor, and margin expansion, supported by R&D investments and a differentiated launch pipeline.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Monitor resolution of Form 483 observations at Daman Formulations facility.
Track future ANDA filings and approvals for the US market in Q1 FY27.
Observe Q1 FY27 financial results for continued revenue and EBITDA growth trends.
MEDIUM RISK Q4 net profit de-growth due to exceptional items and regulatory observations at Daman facility.
💡 Investor Takeaway
Alkem Laboratories reported a record FY26 EBITDA of ₹30,052 million, up 19.6% YoY, with Q4 FY26 total revenue from operations at ₹36,033 million, a 14.6% YoY growth. International sales grew 25.4% YoY in Q4 FY26 to ₹12,223 million.
⚖️ Strengths & Concerns

✅ Positives

  • FY26 EBITDA reached a record high of ₹30,052 million, growing 19.6% YoY, reflecting strong operational performance and cost discipline.
  • International sales demonstrated robust growth of 25.4% YoY in Q4 FY26 to ₹12,223 million and 22.5% YoY in FY26 to ₹46,810 million.

⚠️ Concerns

  • Net Profit (after Non-Controlling interest) for Q4 FY26 saw a YoY de-growth of 22.7%, totaling ₹2,365 million, impacted by exceptional items.
  • An exceptional item in Q4 FY26 included ₹1,917.6 million incremental liability towards gratuity and leave encashment for past service cost.
📅 Company Track Record
Alkem Laboratories previously approved its FY26 results and recommended a final dividend of Rs. 10 per share. This follows a trend of consistent financial reporting and dividend declarations.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Alkem Laboratories' total revenue from operations for Q4 FY26?
Alkem Laboratories' total revenue from operations for Q4 FY26 was ₹36,033 million, a YoY growth of 14.6%.
What was Alkem Laboratories' EBITDA for FY26?
Alkem Laboratories reported an EBITDA of ₹30,052 million for FY26, which is a YoY growth of 19.6%, resulting in an EBITDA margin of 20.4%.
How did Alkem Laboratories' international sales perform in Q4 FY26?
International sales for Alkem Laboratories in Q4 FY26 were ₹12,223 million, reflecting a YoY growth of 25.4%.
What was Alkem Laboratories' Net Profit in Q4 FY26?
Alkem Laboratories' Net Profit (after Non-Controlling interest) for Q4 FY26 was ₹2,365 million, a YoY de-growth of 22.7%.
What was the status of Alkem Laboratories' Daman facility inspection?
The Daman (India) Formulations facility received a Form 483 with 7 observations in April 2026, and the audit response is currently under submission.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.